{"nctId":"NCT02573467","briefTitle":"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203","startDateStruct":{"date":"2015-11-02","type":"ACTUAL"},"conditions":["Sporadic Inclusion Body Myositis"],"count":211,"armGroups":[{"label":"BYM338/bimagrumab 10 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Bimagrumab"]},{"label":"BYM338/bimagrumab 3 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Bimagrumab"]},{"label":"BYM338/bimagrumab 1 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Bimagrumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Bimagrumab","otherNames":["BYM338"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who completed the core study\n* Written informed consent must be obtained before any extension study assessment is performed.\n* Able to communicate well with the investigator.\n* Willing to participate for the entire duration of the extension study with commitment to follow study requirements and procedures.\n\nExclusion Criteria:\n\n* Women who are pregnant\n* Women of child-bearing potential unless they are using highly effective methods of contraception during dosing and for 6 months after the last BYM338 dose.\n* Current use of prohibited treatments\n* History of severe hypersensitivity reaction in the core study\n* History of adverse event(s) (including those from the core study) prior to the start of study drug in the extension study that, in the judgment of the investigator, taking into account the subject's overall status, prevent the subject from entering the extension study\n* Clinically significant abnormal liver function tests\n* Any medical condition or laboratory finding which, in the opinion of the investigator may interfere with participation in the study, might confound the results of the study, or pose an additional safety risk in administering BYM338","healthyVolunteers":false,"sex":"ALL","minimumAge":"36 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.","description":"Safety monitoring was conducted throughout the study. AEs starting on or after the day of first administration of extension study drug until last administration of study drug + 56 days are considered. SAEs starting on or after the day of first administration of extension study drug are considered. Deaths which occurred on or after the day of first administration of extension study drug are considered.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)","description":"The 6MWD test measures the distance (in meters) that a participant can walk in a 6 minute time frame. A positive change from baseline indicates improvement. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":"68.948"},{"groupId":"OG001","value":"9.48","spread":"81.676"},{"groupId":"OG002","value":"-14.26","spread":"81.029"},{"groupId":"OG003","value":"-5.98","spread":"78.817"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.25","spread":"122.002"},{"groupId":"OG001","value":"-9.73","spread":"68.302"},{"groupId":"OG002","value":"-18.66","spread":"81.536"},{"groupId":"OG003","value":"-32.78","spread":"96.494"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.68","spread":"102.549"},{"groupId":"OG001","value":"-50.58","spread":"118.012"},{"groupId":"OG002","value":"-25.08","spread":"95.737"},{"groupId":"OG003","value":"-61.30","spread":"107.399"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-206.65","spread":"281.923"},{"groupId":"OG001","value":"-5.0","spread":"NA"},{"groupId":"OG002","value":"-53.65","spread":"114.322"},{"groupId":"OG003","value":"31.60","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Core Study Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side","description":"Quantitative Muscle Testing (QMT) was used to describe the long-term evolution of quadriceps muscle strength on the right side. The QMT was performed using the same portable fixed dynamometry (PFD) used in the core study. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.29","spread":"31.121"},{"groupId":"OG001","value":"-19.70","spread":"77.820"},{"groupId":"OG002","value":"-5.62","spread":"32.245"},{"groupId":"OG003","value":"-14.22","spread":"27.577"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.43","spread":"41.285"},{"groupId":"OG001","value":"-23.76","spread":"73.729"},{"groupId":"OG002","value":"-17.04","spread":"25.696"},{"groupId":"OG003","value":"-21.02","spread":"31.391"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.92","spread":"35.243"},{"groupId":"OG001","value":"-16.99","spread":"34.379"},{"groupId":"OG002","value":"-18.63","spread":"37.968"},{"groupId":"OG003","value":"-21.91","spread":"39.985"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.64","spread":"NA"},{"groupId":"OG001","value":"33.38","spread":"NA"},{"groupId":"OG002","value":"-19.36","spread":"18.475"},{"groupId":"OG003","value":"-18.24","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Core Study Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score","description":"Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"15.249"},{"groupId":"OG001","value":"1.80","spread":"11.910"},{"groupId":"OG002","value":"3.17","spread":"11.380"},{"groupId":"OG003","value":"5.16","spread":"13.889"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"13.745"},{"groupId":"OG001","value":"5.33","spread":"13.099"},{"groupId":"OG002","value":"6.52","spread":"12.918"},{"groupId":"OG003","value":"7.41","spread":"14.410"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.54","spread":"14.998"},{"groupId":"OG001","value":"8.04","spread":"16.861"},{"groupId":"OG002","value":"5.97","spread":"12.849"},{"groupId":"OG003","value":"7.39","spread":"15.580"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.37","spread":"21.857"},{"groupId":"OG001","value":"10.91","spread":"NA"},{"groupId":"OG002","value":"1.37","spread":"17.655"},{"groupId":"OG003","value":"6.36","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Estimated Annual Number of Falls Per Participant Within Treatment Group","description":"Participants documented any fall occurrences in a paper diary during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.164","spread":null},{"groupId":"OG001","value":"3.879","spread":null},{"groupId":"OG002","value":"3.480","spread":null},{"groupId":"OG003","value":"3.835","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Core Study Baseline in Short Physical Performance Battery (SPPB) Score","description":"The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.73"},{"groupId":"OG001","value":"0.2","spread":"1.61"},{"groupId":"OG002","value":"-0.4","spread":"1.74"},{"groupId":"OG003","value":"-0.3","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.58"},{"groupId":"OG001","value":"-0.1","spread":"1.54"},{"groupId":"OG002","value":"-0.4","spread":"1.69"},{"groupId":"OG003","value":"-0.9","spread":"1.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"3.29"},{"groupId":"OG001","value":"-0.9","spread":"2.77"},{"groupId":"OG002","value":"-1.1","spread":"2.56"},{"groupId":"OG003","value":"-1.3","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"4.24"},{"groupId":"OG001","value":"0.0","spread":"NA"},{"groupId":"OG002","value":"0.3","spread":"2.06"},{"groupId":"OG003","value":"0.0","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change in Muscles of the Thigh","description":"Magnetic resonance imaging (MRI) was planned to be used to characterize changes in muscles of the thigh in a subset of patients.","classes":[]},{"type":"SECONDARY","title":"Number of Patients With Anti-BYM338 Antibodies","description":"Investigated the development of immunogenicity against BYM338.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":53},"commonTop":["Fall","Contusion","Diarrhoea","Skin abrasion","Muscle spasms"]}}}